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Abstract
Hereditary pancreatitis is due to heterozygosity for gain-
of-function mutations in the cationic trypsinogen gene
which result in increased levels of active trypsin within
pancreatic acinar cells and autodigestion of the pan-
creas. The number of disease-causing defects is general-
ly considered to be low. To gain further insight into the
molecular basis of this disorder, DNA sequence analysis
of all five exons was performed in 109 unrelated patients
with idiopathic chronic pancreatitis in order to determine
the variability of the underlying mutations. Two German
females and one German male were carriers of the most
common N29I and R122H mutations (trypsinogen num-
bering system). In a Turkish proband, an arginine (CGT)
to cysteine (TGT) substitution at amino acid position 116
was identified. Family screening demonstrated that the
patient had inherited the mutation from his asymptomat-
ic father and that he had transmitted it to both of his chil-
dren, his daughter being symptomatic since the age of 3
years. In addition, a German male was found to be a het-
erozygote for a D100H (GAC→CAC) amino acid replace-
ment. Our data provide evidence for genetic heterogene-
ity of hereditary pancreatitis. The growing number of cat-
ionic trypsinogen mutations is expected to change cur-
rent mutation screening practices for this disease.
Copyright © 2002 S. Karger AG, Basel
Introduction
Hereditary pancreatitis is a rare autosomal dominant
disorder with about 80% penetrance and variable expres-
sivity [for a review see 1–4]. Onset of disease occurs at a
mean age of 14.1 B 11.9 years [5]. In comparison with
alcoholic pancreatitis, patients suffering from hereditary
pancreatitis are less likely to develop pancreatic calcifica-
tions or diabetes. They also have a lower overall mortality
rate. The risk of pancreatic cancer, however, is increased,
especially if the disease is inherited through the paternal
side of the family, and smoking appears to be an impor-
tant additional risk factor [5].
Since the first report of hereditary pancreatitis in 1952
[6], more than 150 kindreds have been identified world-
wide, the majority of which are of Caucasian ancestry
with a few families reported from Japan [7–13].
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In 1996, advances in molecular genetics enabled two
independent groups to map the hereditary pancreatitis
locus to chromosome 7q35 [14, 15], partially overlapping
the T cell receptor beta locus [16]. Of the eight genes
found in this locus, only two appear to be functional and
to code for cationic and anionic trypsinogen [16–18]. In
the same year, the first disease-specific mutation (R122H;
numbering according to the trypsinogen nomenclature,
corresponding to chy#R117H) was identified in the cat-
ionic trypsinogen gene by Whitcomb et al. [9]. This was
followed by the report of a second common disease-spe-
cific mutation (N29I, corresponding to chy#N21I) in
1997 [19]. The genetic heterogeneity of hereditary pancre-
atitis has been illustrated by the discovery of additional
mutations in exon 1 (TCC deletion at positions –28 to
–30 with respect to the ATG start codon) [11], exon 2
(A16V, D22G, K23R, and P36R), and exon 3 (E79K,
G83E, K92N, and V123M) [11, 20–22]. In addition, the
sequences of three allelic variants (L104P, R116C, and
C139F) have been deposited in the Genbank of the
National Center for Biotechnology Information, National
Library of Medicine, National Institutes of Health, by
Teich and coworkers in November 2000 (accession Nos.
AF315309–AF315311).
To determine the frequency of hereditary pancreatitis
and the heterogeneity of the underlying mutations, we
studied 109 unrelated Caucasian probands with idiopath-
ic chronic pancreatitis. Besides the common N29I and
R122H mutations, two additional amino acid substitu-
tions were identified in this group of patients: a D100H
substitution in a German male with idiopathic chronic
pancreatitis and an R116C mutation in 4 members of a
Turkish family, 2 of them being symptomatic carriers.
Subjects and Methods
Ethical Considerations
Written informed consent was obtained from all participants,
and the research was carried out in accordance with the ethical guide-
lines of the 1975 Declaration of Helsinki.
DNA Isolation and Amplification by PCR
Genomic DNA was extracted from white blood cells using the
QIAGEN (Hilden, Germany) blood minikit and amplified by PCR
with nested primer pairs which flank the five coding exons of the
cationic trypsinogen gene. Each 50-Ìl reaction mixture of the first
round of amplification contained 20 ÌM of each oligonucleotide
primer, 200 ÌM of each dNTP, approximately 300 ng of high-
molecular-weight DNA, and 1.25 U HotStarTaq DNA polymerase
(QIAGEN) in a Tris/KCl/(NH4)2SO4 buffer (pH 8.7) with 1.5 mM
MgCl2 and 1! Q solution. After denaturation at 95°C for 15 min,
DNA was amplified for 25 cycles at 95°C for 20 s, at 53 °C (exon 5),
56°C (exons 1 and 2), 58°C (exon 4), or 61 °C (exon 3) for 20 s, and
at 72°C for 30 s. The second, nested PCR reaction was performed
with 5 Ìl of the first PCR mixture under identical conditions, except
for the primers. The amplification profile included denaturation at
95°C for 20 s, primer annealing at 61°C (exon 3), 63°C (exons 1 and
2), 64°C (exon 5), or 65°C (exon 4) for 20 s, and elongation at 72°C
for 30 s for a total of 40 cycles.
DNA Sequence Analysis
Amplification products were isolated using the QIAquick PCR
purification kit (QIAGEN). Cycle sequencing was performed with
the nested primer set, 3)-dye-labeled dideoxynucleotide triphos-
phates (dye terminators), and AmpliTaq DNA polymerase on an
Applied Biosystems (Foster City, Calif., USA) 377 DNA sequencer.
Mutations were confirmed by second-strand sequencing.
Restriction Fragment Length Polymorphism Analysis
Ten units of restriction endonuclease Bbr PI (Pma CI; 5)-CAC/
GTG-3); Roche Diagnostics, Mannheim, Germany) was used for
mutation detection, as the Arg116 (CGT)→Cys (TGT) substitution
results in the loss of the only Bbr PI site within the amplified exon 3
fragment (PC/GENE; IntelliGenetics, Mountain View, Calif., USA).
After overnight incubation, restriction digests were loaded on 2% low
melting point agarose gels (Gibco BRL Life Technologies, Rockville,
Md., USA), and the DNA fragments were visualized by ethidium
bromide staining and ultraviolet transillumination.
Results
In an attempt to identify patients with hereditary pan-
creatitis and to determine the heterogeneity of the un-
derlying mutations, we have sequenced the coding exons
of the cationic trypsinogen gene in 109 Caucasian patients
with the diagnosis of idiopathic chronic pancreatitis.
One female (*1975) was a heterozygous carrier of the
N29I substitution, and in another female (*1952) and in a
male proband (*1965), the R122H mutation was present.
In addition, 1 male patient (*1960) was found to be a het-
erozygote for an aspartic acid (GAC) to histidine (CAC)
replacement at amino acid position 100 of cationic tryp-
sinogen (D100H; fig. 1). The causal relationship between
this mutation and the chronic pancreatitis present in this
subject could not be proven, because the proband did not
give his consent to further family studies. Comparison
with the amino acid sequences of anionic trypsinogen,
mesotrypsinogen, and chymotrypsinogen demonstrated
that the aspartic acid at position 100 is not strictly con-
served, being replaced by asparagine in anionic trypsino-
gen and mesotrypsinogen and by isoleucine in chymotryp-
sinogen. The D100H substitution could, therefore, be a
rare polymorphism not observed in the other 108 unre-
lated subjects studied thus far. However, the suspicion
that this variant may be of pathogenetic relevance is sup-
228 Digestion 2001;64:226–232 Tautermann/Ruebsamen/Beck/Dertinger/
Drexel/Lohse
ported by the identification of a leucine-to-proline re-
placement at amino acid position 104 (L104P; Genbank
accession No. AF315309) in members of a German fami-
ly suffering from chronic pancreatitis, strongly suggesting
that alterations in this particular region of the molecule
are associated with a genetic predisposition to chronic
pancreatitis.
We also identified 2 subjects, an Italian male (*1964)
and a Turkish female (*1990), who were heterozygotes for
previously also not reported G→A mutations at positions
–79 and –78 with respect to the intron 4/exon 5 border.
Whether these nucleotide substitutions, which occur
within a stretch of four guanines in intron 4, are of any
functional significance remains to be determined.
A fourth amino acid substitution, an arginine-to-cys-
teine exchange at position 116 of cationic trypsinogen
(present in Genbank as TRYP1-R116C allele; accession
No. AF315310), was detected in a Turkish family with 2
members being affected by chronic pancreatitis and is
presented in detail below.
Thirty-four probands were heterozygotes for the al-
ready described intragenic polymorphisms [10–12, 19] in
exon 4 (GAC→GAT; D162D) and in exon 5 (AAC→
AAT; N246N) which, in our experience, are tightly linked
in cis and, therefore, appear to be located on the same
allele. Twenty-six subjects were homozygotes for these
two silent mutations, and 44 patients had inherited the
wild-type sequence on both of their alleles. In 5 cases, only
exons 1–3 were analyzed.
Family Characteristics
The 28-year-old Turkish male R.D. was admitted to
the Department of Internal Medicine of the Landeskran-
kenhaus Feldkirch, Austria, in February 2000 with a 1-
year history of recurrent upper abdominal pain and a
weight loss of 9 kg. The patient had no past history of
illness or alcohol abuse, and he was not taking regular
medications.
On examination, he had spontaneous and palpatory
evoked pain in the right upper abdomen. The leukocyte
count was 9.8 ! 109/l, liver transaminases were in the
high-normal range (AST 19 U/l, ALT 28 U/l), and the Á-
glutamyltransferase concentration was increased three-
fold (83 U/l), while the lipase and alkaline phosphatase
levels were normal.
Imaging diagnostics (abdominal X-ray, CT scan) dem-
onstrated pancreatic calcifications in head and body.
ERCP verified the pancreatic duct irregularities and a sin-
gle pancreatic duct stone in the head first detected by
ultrasonography. Due to papillary stenosis, a papillotomy
was carried out, and a 10-Fr stent was implanted into the
pancreatic duct. A minor secondary stenosis of the bile
duct was also treated with papillotomy, as a result of
which normal liver enzyme values were obtained. Liver
disease had initially been ruled out serologically and
through biopsy.
The patient has 2 children, his daughter R.D. (*1993)
being symptomatic twice a year since the age of 3 years
with upper abdominal pain radiating to the back. Trans-
abdominal ultrasound and magnetic resonance cholangio-
pancreatography, performed in May 2001, did not show
any complications associated with chronic pancreatitis
(e.g., ductal irregularities and dilatation, calcifications,
pseudocysts). Exocrine function tests, done at the same
time, revealed no signs of pancreatic dysfunction.
Knowledge of additional family members with recur-
rent attacks of abdominal pain or symptoms typical of
diabetes mellitus was negated by the proband.
Genetic Analyses
DNA cycle sequencing of exons 1–5 of the proband’s
cationic trypsinogen gene revealed a single C→T substi-
tution at nucleotide position 146 of exon 3 (numbering
relative to the intron 2/exon 3 border), for which the
patient was heterozygous. This mutation results in the
replacement of arginine (CGT), residue 116 of cationic
trypsinogen, by cysteine (TGT; fig. 2). After identification
of the putative mutation, further molecular genetic analy-
ses were carried out in the proband’s immediate relatives:
his mother Z.D. (*1947), his father M.D. (*1946), his
daughter R.D. (*1993), and his son E.D. (*1996). Other
family members were not available for testing. DNA
sequence analysis demonstrated that, except for the moth-
er, all subjects studied were heterozygotes for the R116C
substitution. These results were confirmed by restriction
fragment length polymorphism analysis, as software-
assisted screening for polymorphic restriction enzyme
sites demonstrated loss of a Bbr PI (Pma CI) site (5)-CAC/
GTG-3)) as a consequence of the C→T base exchange.
Agarose gel electrophoresis of Bbr-PI-digested exon 3 am-
plification products also identified the proband, his fath-
er, and his 2 children as heterozygous carriers of the muta-
tion by the presence of three instead of two fragments,
while the mother served as normal control (fig. 3).
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Fig. 1. Sequence analysis of exon 3 of the cationic trypsinogen gene
in a control subject and in proband K.W. The five exons of the cat-
ionic trypsinogen gene (black boxes) and the intervening intron
sequences (lines) as well as the G→C mutation (boxed) in exon 3,
which results in the substitution of aspartic acid (GAC), residue 100,
by histidine (CAC), are shown in the upper panel. The lower panel
depicts the results of the DNA sequence analysis of exon 3 PCR prod-
ucts from a control (upper part) and from the heterozygous carrier
K.W. (lower part).
Fig. 2. Sequence analysis of exon 3 of the cationic trypsinogen gene
in a control subject and in patient R.D. The schematic diagram of the
structure of the human cationic trypsinogen gene (upper panel) illus-
trates the location of the C→T mutation (boxed) which results in the
replacement of amino acid 116, arginine (CGT), by cysteine (TGT).
The lower panel contains the corresponding sequencing electrophe-
rograms from a control (upper part) and from the heterozygous pro-
band R.D. (lower part).
Discussion
Hereditary pancreatitis is indistinguishable from other
forms of chronic pancreatitis in terms of clinical, labora-
tory, radiological, and histopathological features. Suspi-
cion is raised in case a subject presents with recurrent epi-
sodes of pancreatitis, beginning in childhood or adoles-
cence in the absence of etiological factors such as alcohol
abuse, hypertriglyceridemia, and hyperparathyroidism
[for a review see 23].
The disorder has been shown to be caused by muta-
tions in the cationic trypsinogen gene. Suggested criteria
for genetic testing are one or two relatives with pancreati-
tis, patients with idiopathic chronic pancreatitis before
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Fig. 3. Bbr PI restriction enzyme digestion
of PCR-amplified exon 3 products of the cat-
ionic trypsinogen gene from the mother Z.D.
(–/–), the father M.D. (+/–), the proband
R.D. (+/–), the son E.D. (+/–), and the
daughter R.D., Jr (+/–) for detection of the
R116C substitution. Exon 3 was amplified
from genomic DNA using primer pair CT3–
1 and CT3–2, as shown in the upper panel.
Below, the fragment sizes produced by Bbr
PI digest in the absence and in the heteroal-
lelic presence of the C→T gene mutation are
illustrated. The lower panel contains an aga-
rose gel electropherogram of exon 3 amplifi-
cation products from the heterozygous pro-
band and his immediate relatives after diges-
tion with the restriction enzyme Bbr PI. A
nucleic acid molecular size standard (M) was
loaded in the left and in the right lanes, and
the size of the fragments (in base pairs) is
given on the left side. The sizes of the
digested PCR products are shown on the
right side.
the age of 30 years, and probands with pancreatic carcino-
ma before the age of 45 years. A facultative criterion is
recurrent and unclear abdominal pain during childhood
independent of amylase and lipase levels [24].
A negative family history, however, does not exclude
the diagnosis of hereditary pancreatitis. Because of the
incomplete phenotypic penetrance of approximately
80%, a new index patient has a 20% probability that his
parents are asymptomatic carriers of the disease. In addi-
tion, the patients may be not aware of a positive fam-
ily history, as their relatives can (1) be misdiagnosed,
(2) have only mild symptoms, or (3) present with just one
clinical feature such as diabetes mellitus or chronic un-
diagnosed abdominal pain [25].
Thus far, eleven different mutations in exons 1 (TCC
deletion at position –28 to –30 with respect to the ATG
start codon), 2 (A16V, D22G, K23R, N29I, and P36R),
and 3 (E79K, G83E, K92N, R122H, and V123M) of the
cationic trypsinogen gene have been described in the liter-
ature as the molecular basis of hereditary pancreatitis [9,
11, 19–22]. In addition, three allelic variants (L104P,
R116C, and C139F) have been reported to Genbank (ac-
cession Nos. AF315309–AF315311).
Trypsinogen is a serine protease proenzyme (zymogen)
synthesized by the pancreatic acinar cells. It is converted
to trypsin in the duodenum by enterokinase which hydro-
lyzes the peptide bond between the eight-amino-acid tryp-
sinogen activation peptide and the mature protein. Tryp-
sin in turn activates itself as well as intestinal digestive
enzymes by hydrolysis of the respective activation pep-
tides. Because trypsin is such a potent protease, defense
mechanisms exist to prevent prolonged action of trypsin if
D100H and R116C Mutations of Cationic
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prematurely activated within the pancreas. Of these, pan-
creatic secretory trypsin inhibitor is the most important.
By competitive inhibition at the catalytic site, it can deac-
tivate up to 20% of the trypsin molecules. The remaining
trypsin is hydrolyzed by other trypsin molecules or by the
trypsinlike enzymes mesotrypsin and molecule Y through
proteolytic cleavage of the hinge region between the N-
and C-terminal domains at residue R122 (in the trypsino-
gen nomenclature) which is believed to represent the pri-
mary proteolysis site [26–32].
The most common R122H mutation eliminates this
site of hydrolysis and, therefore, renders trypsin resistant
to autolysis, resulting in higher concentrations of trypsin,
autodigestion of the pancreas, and pancreatitis [1–4, 9].
Both the R122H and the N29I substitution, the second
most common cause of hereditary pancreatitis, have also
been shown to significantly enhance autoactivation of
human cationic trypsinogen in vitro which in turn leads to
higher levels of trypsin being generated in pancreatic aci-
nar cells [33]. An alternative hypothesis has been put for-
ward by Whitcomb and coworkers [2, 4]: The conforma-
tional change associated with the N29I mutation is pro-
posed to result in the formation of a salt bridge between
residues E32 and R122 which in turn prevents the A117-
L128 side chain from rotating outward, a movement
which appears to be necessary to expose the peptide bond
between R122 and V123 to other trypsin and trypsinlike
molecules for hydrolytic cleavage.
The R116C amino acid substitution described in this
study may have a similar effect on the motion of the semi-
flexible side chain containing R122. As the mutation is
located adjacent to the twelve-residue-connecting side
chain A117-L128, it is conceivable that the R116C re-
placement interferes with the movement of the oligopep-
tide chain into the hydrolysis-sensitive position, thereby
preventing the critical autolysis site at R122 from being
attacked. This would result in resistance to trypsin inacti-
vation, enhanced trypsinogen activation, acinar cell au-
todigestion, and acute pancreatitis.
The R116C substitution occurs at a position not con-
served among the human anionic trypsinogen, mesotryp-
sinogen, and chymotrypsinogen proteins where arginine
is replaced by proline [3]. Computer modeling (PC/
GENE) of cationic trypsinogen with either cysteine or
proline at position 116 demonstrated, however, that cys-
teine, but not proline, significantly decreases the chain
flexibility of residues 112–118 of cationic trypsinogen, as
cysteine, in contrast to proline, is a rigid residue [34]. In
addition, while proline is an accepted amino acid substi-
tution for arginine, as suggested by the empirical Dayhoff
substitutability matrix (6% of the total changes detected
for arginine in the sequences of related proteins), cysteine
is not (0.9% of the total changes) [35].
In approximately 4–5% of our idiopathic chronic pan-
creatitis cases, the disease is caused by a mutation in the
cationic trypsinogen gene. In contrast to earlier assump-
tions, however, the number of autosomal dominant muta-
tions associated with hereditary pancreatitis appears to be
unexpectedly large. This mutational heterogeneity of cat-
ionic trypsinogen alleles is expected to have practical
implications. In our opinion, it is certainly not sufficient
to screen patients with chronic pancreatitis only for the
two most prevalent N29I and R122H mutations in order
to reach satisfactory carrier detection levels. Although
most of the other mutated alleles appear to be much rarer,
at present the only way to detect all carriers and all possi-
ble mutations is to sequence all five exons of the cationic
trypsinogen gene. This is easily feasible despite the fact
that its sequence is highly homologous to that of other
trypsinogen genes within the T cell receptor beta locus [9].
The cost of this approach will be higher than that of other
mutation screening tests, but it has the clear advantage of
providing a definitive answer as to whether the patient in
question suffers from hereditary pancreatitis or not. This
has significant clinical ramifications for the individual
and his family with regard to disease course and pancreat-
ic cancer risk.
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